Invasive Pneumococcal Disease Associated with Fanconi-Like Syndrome

Trends in invasive pneumococcal disease-associated hospitalizations.

BACKGROUND The heptavalent pneumococcal conjugate vaccine was licensed in the United States in 2000 for use in infants and children. Postlicensure surveillance revealed substantial regional and national decreases in invasive pneumococcal disease. It is not known whether widespread vaccine use has led to a concomitant decrease in invasive pneumococcal disease-associated hospitalization rates. ...

Salicylate-induced Fanconi-like syndrome

Salicylate intoxication is a very common problem in everyday clinical practice. We describe a new case of salicylate-induced reversible Fanconi's syndrome in a 28-year-old Cypriot male who ingested 50 g of acetylsalicylic acid with suicidal intent. To our knowledge, this is the second case ever described. It is suggested that clinicians should be aware of this salicylate intoxication-induced co...

Invasive pneumococcal disease.

INTRODUCTION Streptococcus pneumoniae, the pneumococcus, is a Gram-positive diplococcus with more than 90 serotypes determined by the polysaccharide composition of its capsule. It is carried asymptomatically in approximately 50% of people.1 It can cause both non-invasive and invasive disease. Invasive pneumococcal disease (IPD) refers to disease in which the bacterium enters a sterile site such...

Fanconi syndrome associated with cidofovir therapy.

Cidofovir is a nucleoside analog with potent activity against cytomegalovirus (CMV); it is 10-fold more potent than ganciclovir in vitro (4). Its phosphorylated metabolite has an intracellular half-life greater than 48 h, and it is estimated that intracellular phosphorylated cidofovir may inhibit CMV replication for 5 to 10 days (1). The proposed maintenance treatment in patients presenting wit...

fanconi syndrome associated with valporic acid: a case report